{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:06:11Z","timestamp":1773669971934,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171399"],"award-info":[{"award-number":["82171399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371413"],"award-info":[{"award-number":["82371413"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00415-025-13563-6","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:19:00Z","timestamp":1765437540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A pilot study of telitacicept in predominantly immune-mediated necrotizing myopathy, retrospective analysis of a monocentric Chinese cohort"],"prefix":"10.1007","volume":"273","author":[{"given":"Wei","family":"Xiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-2544","authenticated-orcid":false,"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"13563_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41572-021-00325-7","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, Mammen AL, Miller FW (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7:87. https:\/\/doi.org\/10.1038\/s41572-021-00325-7","journal-title":"Nat Rev Dis Primers"},{"key":"13563_CR2","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH et al (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"13563_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, Vencovsky J, de Visser M, Hughes RA (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14:337\u2013345. https:\/\/doi.org\/10.1016\/j.nmd.2004.02.006","journal-title":"Neuromuscul Disord"},{"key":"13563_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s11926-996-0023-5","volume":"8","author":"AN Baer","year":"2006","unstructured":"Baer AN (2006) Differential diagnosis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 8:178\u2013187. https:\/\/doi.org\/10.1007\/s11926-996-0023-5","journal-title":"Curr Rheumatol Rep"},{"key":"13563_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","volume":"19","author":"T Khoo","year":"2023","unstructured":"Khoo T, Lilleker JB, Thong BY, Leclair V, Lamb JA, Chinoy H (2023) Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol 19:695\u2013712. https:\/\/doi.org\/10.1038\/s41584-023-01033-0","journal-title":"Nat Rev Rheumatol"},{"key":"13563_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11926-018-0726-4","volume":"20","author":"V Leclair","year":"2018","unstructured":"Leclair V, Lundberg IE (2018) New myositis classification criteria-what we have learned since Bohan and Peter. Curr Rheumatol Rep 20:18. https:\/\/doi.org\/10.1007\/s11926-018-0726-4","journal-title":"Curr Rheumatol Rep"},{"key":"13563_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, Lilleker JB, Vencovsky J, Chazarain L, Danko K et al (2019) Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 101:48\u201355. https:\/\/doi.org\/10.1016\/j.jaut.2019.04.001","journal-title":"J Autoimmun"},{"key":"13563_CR8","doi-asserted-by":"publisher","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W (2018) 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. Neuromuscul Disord: NMD 28:87\u201399. https:\/\/doi.org\/10.1016\/j.nmd.2017.09.016","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"13563_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.55563\/clinexprheumatol\/yizkja","volume":"43","author":"F Fattorini","year":"2025","unstructured":"Fattorini F, Conticini E, Dourado E, Bottazzi F, Bruno L, Diomedi M, Schmidt J, Carli L, Cavagna L, Barsotti S (2025) Idiopathic inflammatory myopathies: one year in review 2024. Clin Exp Rheumatol 43:167\u2013177. https:\/\/doi.org\/10.55563\/clinexprheumatol\/yizkja","journal-title":"Clin Exp Rheumatol"},{"key":"13563_CR10","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/s2665-9913(23)00322-3","volume":"6","author":"CM Connolly","year":"2024","unstructured":"Connolly CM, Gupta L, Fujimoto M, Machado PM, Paik JJ (2024) Idiopathic inflammatory myopathies: current insights and future frontiers. Lancet Rheumatol 6:e115\u2013e127. https:\/\/doi.org\/10.1016\/s2665-9913(23)00322-3","journal-title":"Lancet Rheumatol"},{"key":"13563_CR11","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","volume":"387","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Cs\u00f6rg\u0151 Z, Dimachkie MM, Griger Z, Moiseev S, Oddis C, Schiopu E, Vencovsk\u00fd J et al (2022) Trial of intravenous immune globulin in dermatomyositis. N Engl J Med 387:1264\u20131278. https:\/\/doi.org\/10.1056\/NEJMoa2117912","journal-title":"N Engl J Med"},{"key":"13563_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","volume":"14","author":"CV Oddis","year":"2018","unstructured":"Oddis CV, Aggarwal R (2018) Treatment in myositis. Nat Rev Rheumatol 14:279\u2013289. https:\/\/doi.org\/10.1038\/nrrheum.2018.42","journal-title":"Nat Rev Rheumatol"},{"key":"13563_CR13","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, Wan G, Nelson WW (2017) Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther 39:2216\u20132229. https:\/\/doi.org\/10.1016\/j.clinthera.2017.09.011","journal-title":"Clin Ther"},{"key":"13563_CR14","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Telitacicept: first approval. Drugs 81:1671\u20131675. https:\/\/doi.org\/10.1007\/s40265-021-01591-1","journal-title":"Drugs"},{"key":"13563_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y (2021) Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43:666\u2013673. https:\/\/doi.org\/10.1080\/08923973.2021.1973493","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"13563_CR16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s10067-025-07348-5","volume":"44","author":"F Fang","year":"2025","unstructured":"Fang F, Duan H, Ding S (2025) Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study. Clin Rheumatol 44:1113\u20131122. https:\/\/doi.org\/10.1007\/s10067-025-07348-5","journal-title":"Clin Rheumatol"},{"key":"13563_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001074","volume":"10","author":"HZ Jin","year":"2023","unstructured":"Jin HZ, Li YJ, Wang X, Li Z, Ma B, Niu L, Wang P, Pan HF, Li SD, Bao W et al (2023) Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study. Lupus Sci Med 10:e001074. https:\/\/doi.org\/10.1136\/lupus-2023-001074","journal-title":"Lupus Sci Med"},{"key":"13563_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","volume":"63","author":"D Xu","year":"2024","unstructured":"Xu D, Fang J, Zhang S, Huang C, Huang C, Qin L, Li X, Chen M, Liu X, Liu Y et al (2024) Efficacy and safety of telitacicept in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology 63:698\u2013705. https:\/\/doi.org\/10.1093\/rheumatology\/kead265","journal-title":"Rheumatology"},{"key":"13563_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, Li G, Fu P, Xing G, Zheng H, Chen N, Wang C, Luo P et al (2023) Randomized phase 2 trial of Telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 8:499\u2013506. https:\/\/doi.org\/10.1016\/j.ekir.2022.12.014","journal-title":"Kidney Int Rep"},{"key":"13563_CR20","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1111\/cns.13904","volume":"28","author":"J Ding","year":"2022","unstructured":"Ding J, Jiang X, Cai Y, Pan S, Deng Y, Gao M, Lin Y, Zhao N, Wang Z, Yu H et al (2022) Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: a single-center, single-arm, open-label study. CNS Neurosci Ther 28:1613\u20131623. https:\/\/doi.org\/10.1111\/cns.13904","journal-title":"CNS Neurosci Ther"},{"key":"13563_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241251476","volume":"17","author":"J Lin","year":"2024","unstructured":"Lin J, Li Y, Gui M, Bu B, Li Z (2024) Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study. Ther Adv Neurol Disord 17:17562864241251476. https:\/\/doi.org\/10.1177\/17562864241251476","journal-title":"Ther Adv Neurol Disord"},{"key":"13563_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae601","author":"H Gao","year":"2024","unstructured":"Gao H, Lin J, Yang M, Gui M, Ji S, Bu B, Li Y (2024) Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keae601","journal-title":"Rheumatology"},{"key":"13563_CR23","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/rheumatology\/kead281","volume":"63","author":"G Marder","year":"2024","unstructured":"Marder G, Quach T, Chadha P, Nandkumar P, Tsang J, Levine T, Schiopu E, Furie R, Davidson A, Narain S (2024) Belimumab treatment of adult idiopathic inflammatory myopathy. Rheumatology 63:742\u2013750. https:\/\/doi.org\/10.1093\/rheumatology\/kead281","journal-title":"Rheumatology"},{"key":"13563_CR24","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/art.20349","volume":"50","author":"LG Rider","year":"2004","unstructured":"Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FW (2004) International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50:2281\u20132290. https:\/\/doi.org\/10.1002\/art.20349","journal-title":"Arthritis Rheum"},{"key":"13563_CR25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG et al (2017) 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 76:792\u2013801. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211400","journal-title":"Ann Rheum Dis"},{"key":"13563_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10165-012-0627-8","volume":"23","author":"T Yokoyama","year":"2013","unstructured":"Yokoyama T, Shimizu M, Ishikawa S, Ueno K, Hamaguchi Y, Takehara K, Yachie A (2013) Accumulation of mature B cells in the inflamed muscle tissue of a patient with anti-155\/140 antibody-positive juvenile dermatomyositis. Mod Rheumatol 23:167\u2013171. https:\/\/doi.org\/10.1007\/s10165-012-0627-8","journal-title":"Mod Rheumatol"},{"key":"13563_CR27","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00401-009-0570-8","volume":"118","author":"A Brunn","year":"2009","unstructured":"Brunn A, Hans VJ, Vogelgesang S, Deckert M (2009) Inflammatory myopathy with abundant macrophages and dermatomyositis: two stages of one disorder or two distinct entities? Acta Neuropathol 118:793\u2013801. https:\/\/doi.org\/10.1007\/s00401-009-0570-8","journal-title":"Acta Neuropathol"},{"key":"13563_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12016-025-09047-0","volume":"68","author":"T Liu","year":"2025","unstructured":"Liu T, Chen B, Yin G, Xie Q (2025) Targeting B cells for the treatment of idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 68:40. https:\/\/doi.org\/10.1007\/s12016-025-09047-0","journal-title":"Clin Rev Allergy Immunol"},{"key":"13563_CR29","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ana.24902","volume":"81","author":"L Arouche-Delaperche","year":"2017","unstructured":"Arouche-Delaperche L, Allenbach Y, Amelin D, Preusse C, Mouly V, Mauhin W, Tchoupou GD, Drouot L, Boyer O, Stenzel W et al (2017) Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol 81:538\u2013548. https:\/\/doi.org\/10.1002\/ana.24902","journal-title":"Ann Neurol"},{"key":"13563_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","volume":"24","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F (2013) The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 24:203\u2013215. https:\/\/doi.org\/10.1016\/j.cytogfr.2013.04.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"13563_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13075-018-1650-8","volume":"20","author":"O Kry\u0161t\u016ffkov\u00e1","year":"2018","unstructured":"Kry\u0161t\u016ffkov\u00e1 O, Hulejov\u00e1 H, Mann HF, Pecha O, P\u016ftov\u00e1 I, Ekholm L, Lundberg IE, Vencovsk\u00fd J (2018) Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis. Arthritis Res Ther 20:158. https:\/\/doi.org\/10.1186\/s13075-018-1650-8","journal-title":"Arthritis Res Ther"},{"key":"13563_CR32","doi-asserted-by":"publisher","first-page":"1177721","DOI":"10.3389\/fimmu.2023.1177721","volume":"14","author":"PO Carstens","year":"2023","unstructured":"Carstens PO, M\u00fcllar LM, Wrede A, Zechel S, Wachowski MM, Brandis A, Krause S, Zierz S, Schmidt J (2023) Skeletal muscle fibers produce B-cell stimulatory factors in chronic myositis. Front Immunol 14:1177721. https:\/\/doi.org\/10.3389\/fimmu.2023.1177721","journal-title":"Front Immunol"},{"key":"13563_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","volume":"96","author":"JR Myette","year":"2019","unstructured":"Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z et al (2019) A proliferation inducing ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int 96:104\u2013116. https:\/\/doi.org\/10.1016\/j.kint.2019.01.031","journal-title":"Kidney Int"},{"key":"13563_CR34","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2007-09-110858","volume":"111","author":"E Belnoue","year":"2008","unstructured":"Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, Schneider P, Huard B, Lambert PH, Siegrist CA (2008) APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111:2755\u20132764. https:\/\/doi.org\/10.1182\/blood-2007-09-110858","journal-title":"Blood"},{"key":"13563_CR35","doi-asserted-by":"publisher","first-page":"1051609","DOI":"10.3389\/fimmu.2022.1051609","volume":"13","author":"C Zhen","year":"2022","unstructured":"Zhen C, Hou Y, Zhao B, Ma X, Dai T, Yan C (2022) Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Front Immunol 13:1051609. https:\/\/doi.org\/10.3389\/fimmu.2022.1051609","journal-title":"Front Immunol"},{"key":"13563_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","volume":"71","author":"R Cornelis","year":"2021","unstructured":"Cornelis R, Chang HD, Radbruch A (2021) Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells. Curr Opin Immunol 71:97\u2013102. https:\/\/doi.org\/10.1016\/j.coi.2021.06.012","journal-title":"Curr Opin Immunol"},{"key":"13563_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-020-01431-7","volume":"15","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang W, Liu Y, Wang Z, Yuan Y (2020) Factors associated with refractory autoimmune necrotizing myopathy with anti-signal recognition particle antibodies. Orphanet J Rare Dis 15:181. https:\/\/doi.org\/10.1186\/s13023-020-01431-7","journal-title":"Orphanet J Rare Dis"},{"key":"13563_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.777502","volume":"12","author":"BB Cui","year":"2021","unstructured":"Cui BB, Tian YR, Ma XY, Yin G, Xie Q (2021) Belimumab for immune-mediated necrotizing myopathy associated with anti-SRP antibodies: a case report and retrospective review of patients treated with anti-b-cell therapy in a single center and literature. Front Immunol 12:777502. https:\/\/doi.org\/10.3389\/fimmu.2021.777502","journal-title":"Front Immunol"},{"key":"13563_CR39","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jaad.2024.04.060","volume":"91","author":"Y Liu","year":"2024","unstructured":"Liu Y, Li Y, Shen T, Zhang H, Luo S, Zhang Q, Dang X, Li X, Long H (2024) Belimumab ameliorates symptoms and disease activity in patients with dermatomyositis and juvenile dermatomyositis refractory to standard therapy: a retrospective observational study. J Am Acad Dermatol 91:524\u2013527. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.060","journal-title":"J Am Acad Dermatol"},{"key":"13563_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/art.43417","author":"C Luo","year":"2025","unstructured":"Luo C, Su S, Liu J, Lin J, Song J, Chen Z, Peng Y, Jiang L, Jia M, Wang L et al (2025) The efficacy of telitacicept in childhood-onset systemic lupus erythematosus: a prospective multi-center cohort study with IPTW-adjusted comparison to a historical control group treated with Belimumab. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.43417","journal-title":"Arthritis Rheumatol"},{"key":"13563_CR41","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","volume":"82","author":"ME DeWane","year":"2020","unstructured":"DeWane ME, Waldman R, Lu J (2020) Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 82:267\u2013281. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1309","journal-title":"J Am Acad Dermatol"},{"key":"13563_CR42","doi-asserted-by":"publisher","first-page":"e739","DOI":"10.1212\/wnl.0000000000013176","volume":"98","author":"J Tanboon","year":"2022","unstructured":"Tanboon J, Inoue M, Saito Y, Tachimori H, Hayashi S, Noguchi S, Okiyama N, Fujimoto M, Nishino I (2022) Dermatomyositis: muscle pathology according to antibody subtypes. Neurology 98:e739\u2013e749. https:\/\/doi.org\/10.1212\/wnl.0000000000013176","journal-title":"Neurology"},{"key":"13563_CR43","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnen\/nlab071","volume":"80","author":"A Pestronk","year":"2021","unstructured":"Pestronk A, Choksi R (2021) Pathology features of immune and inflammatory myopathies, including a polymyositis pattern, relate strongly to serum autoantibodies. J Neuropathol Exp Neurol 80:812\u2013820. https:\/\/doi.org\/10.1093\/jnen\/nlab071","journal-title":"J Neuropathol Exp Neurol"},{"key":"13563_CR44","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/bjd.15006","volume":"176","author":"C Huard","year":"2017","unstructured":"Huard C, Gull\u00e0 SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA (2017) Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis. Br J Dermatol 176:1224\u20131230. https:\/\/doi.org\/10.1111\/bjd.15006","journal-title":"Br J Dermatol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13563-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13563-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13563-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:58:30Z","timestamp":1773665910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13563-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["13563"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13563-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Medical Ethics Committee of Xiangya Hospital, Central South University (No. 202408003).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants gave written informed consent before completing a comprehensive medical evaluation and treatment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"20"}}